TY - JOUR
T1 - Kidney disease in the setting of HIV infection
T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
AU - Conference Participants
AU - Swanepoel, Charles R.
AU - Atta, Mohamed G.
AU - D'Agati, Vivette D.
AU - Estrella, Michelle M.
AU - Fogo, Agnes B.
AU - Naicker, Saraladevi
AU - Post, Frank A.
AU - Wearne, Nicola
AU - Winkler, Cheryl A.
AU - Cheung, Michael
AU - Wheeler, David C.
AU - Winkelmayer, Wolfgang C.
AU - Wyatt, Christina M.
AU - Abu-Alfa, Ali
AU - Adu, Dwomoa
AU - Agodoa, Lawrence Y.
AU - Alpers, Charles E.
AU - Arogundade, Fatiu A.
AU - Ashuntantang, Gloria
AU - Bagnis, Corinne I.
AU - Bhimma, Raj
AU - Brocheriou, Isabelle
AU - Cohen, Arthur H.
AU - Cohen, Karen
AU - Cook, H. Terence
AU - de Seigneux, Sophie
AU - Fabian, June
AU - Finkelstein, Fredric O.
AU - Haas, Mark
AU - Hamzah, Lisa
AU - Hendry, Bruce M.
AU - Imonje, Valentine
AU - Jennette, J. Charles
AU - Kimmel, Paul L.
AU - Klotman, Mary E.
AU - Klotman, Paul E.
AU - Larsen, Chris P.
AU - McCulloch, Mignon I.
AU - Mosiane, Pulane
AU - Nast, Cynthia C.
AU - Okpechi, Ikechi G.
AU - Ray, Patricio E.
AU - Rosenberg, Avi Z.
AU - Ross, Michael J.
AU - Ryom, Lene
AU - Truong, Luan
AU - Ulasi, Ifeoma
AU - Vogt, Liffert
AU - Zeier, Martin
N1 - Funding Information:
CRS declared owning stock equity from Aspen. MGA declared having received research support from National Institute on Drug Abuse and National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). VDD declared having received research support from NIH/NIDDK. MME declared having received research support from NIH/NIDDK. FAP declared having received consultancy fees from Gilead Sciences, Merck Sharp & Dohme, and ViiV Healthcare; speaker honoraria from Astellas, Gilead Sciences, and Janssen; and research support from Gilead Sciences and ViiV Healthcare. NW declared having received consultancy fees from Adcock Ingram and research support from Medical Research Council of South Africa. DCW declared having received consultancy fees from Akebia, Amgen, Bio Nano Consulting, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Otsuka, UCB Celltech, and Vifor Fresenius Medical Care Renal Pharma; speaker honoraria from Amgen, Fresenius Medical Care, Janssen, Vifor Fresenius Medical Care Renal Pharma, and ZS Pharma; and research support from Australian National Health & Medical Research Council, British Heart Foundation, Healthcare Quality Improvement Partnership, Kidney Research UK, and National Institute for Health Research. WCW declared having received consultancy fees from Akebia, AMAG Pharmaceuticals, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Medtronic, Relypsa, and Vifor Fresenius Medical Care Renal Pharma. All the other authors declared no competing interests.
Funding Information:
The conference was sponsored by KDIGO and jointly held with African Association of Nephrology (AFRAN).
Publisher Copyright:
© 2017 International Society of Nephrology
PY - 2018/3
Y1 - 2018/3
N2 - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.
AB - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.
KW - APOL1
KW - CKD progression
KW - HIV
KW - antiretroviral therapy
KW - immune complex kidney disease
KW - podocytopathy
KW - renal pathology
UR - http://www.scopus.com/inward/record.url?scp=85041607294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041607294&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2017.11.007
DO - 10.1016/j.kint.2017.11.007
M3 - Article
C2 - 29398134
AN - SCOPUS:85041607294
VL - 93
SP - 545
EP - 559
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 3
ER -